Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to $452,000.

  • Biodesix's Gains from Investment Securities rose 140.43% to $452,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 144.08%. This contributed to the annual value of $4.2 million for FY2024, which is 103.97% up from last year.
  • Biodesix's Gains from Investment Securities amounted to $452,000 in Q3 2025, which was down 93.41% from $6.9 million recorded in Q2 2025.
  • Biodesix's 5-year Gains from Investment Securities high stood at $6.9 million for Q2 2025, and its period low was -$58,000 during Q4 2023.
  • Over the past 3 years, Biodesix's median Gains from Investment Securities value was $452,000 (recorded in 2025), while the average stood at $1.6 million.
  • In the last 5 years, Biodesix's Gains from Investment Securities plummeted by 123.97% in 2023 and then soared by 57,266.67% in 2025.
  • Over the past 5 years, Biodesix's Gains from Investment Securities (Quarterly) stood at $639,000 in 2021, then skyrocketed by 240.38% to $242,000 in 2022, then crashed by 123.97% to -$58,000 in 2023, then skyrocketed by 936.21% to $485,000 in 2024, then skyrocketed by 140.43% to $452,000 in 2025.
  • Its last three reported values are $452,000 in Q3 2025, $6.9 million for Q2 2025, and $6.5 million during Q1 2025.